Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.

Adding obinutuzumab later to acalabrutinib/venetoclax therapy—and only for patients with an incomplete response—achieves the same remission rates as upfront administration. This delayed approach improves overall survival by avoiding early, severe infections, particularly COVID-19, associated with the antibody.

The BRUIN-313 trial successfully compared pirtobrutinib to bendamustine-rituximab (BR). However, BR is no longer the frontline standard of care. This 'straw man' comparator makes it difficult to position pirtobrutinib against current preferred treatments like other BTK inhibitors or venetoclax regimens, limiting immediate clinical applicability.

An MD Anderson study suggests adding obinutuzumab later in treatment only for patients failing to achieve undetectable MRD, rather than upfront for all. This "delayed add-on" strategy improves the safety profile by reducing rates of severe infection and neutropenia while reserving the potent antibody for patients who need it most.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

While pirtobrutinib was already used off-label per NCCN guidelines, its official FDA approval provides a government-sanctioned alternative, forcing a direct decision between it and a venetoclax-based regimen for patients relapsing on a prior BTK inhibitor.

Clinical trial experience shows that delaying the administration of obinutuzumab in an Acalabrutinib-Venetoclax-Obinutuzumab (AVO) triplet regimen improves patient tolerability. This sequencing strategy allows clinicians to enhance response with the antibody later, if needed, while minimizing upfront side effects.

Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.